Vapotherm announced today that it entered into a definitive merger agreement that will result in the company going private. The Exeter, New Hampshire-based developer of non-invasive respiratory support technologies, was listed as VAPO on the OTCQX. Last December, the NYSE commenced delisting proceedings against the company, suspending trading and leading to the OTCQX move. At […]
Vapotherm
VapoTherm misses in Q3, lowers guidance
VapoTherm (NYSE:VAPO) shares fell this morning on third-quarter results that came up short of the consensus forecast. The Exeter, New Hampshire-based company posted losses of $91.8 million. That equals 98¢ per share on sales of $13.55 million for the three months ended Sept. 30, 2022. VapoTherm registered a massive bottom-line slide deeper into the red on […]
How medtech is tackling supply chain challenges
Join us at DeviceTalks Boston on May 10-11 to hear how medical device companies are propping open supply lines and ensuring a steady flow of products to customers in a constantly changing world. Sharing best practices is more important than ever because supply chain challenges aren’t expected to diminish post-pandemic. That’s because superstorms, fires, droughts and other extreme […]
Vapotherm announces executive leadership changes
Vapotherm this week announced that it has appointed Brian Lawrence as senior VP and chief technology officer and Dorota McKay as controller and chief accounting officer, effective immediately. Prior to joining the company, Lawrence was chief technology officer and general manager of Gravity Diagnostics where he was responsible for technology and innovation programs across the […]
COVID-19 drives sales outlook boost for Vapotherm
VapoTherm (NYSE:VAPO) yesterday released an update increasing its financial guidance for the fourth quarter of fiscal 2020. In November, the Exeter, N.H.-based respiratory distress treatment developer projected fourth-quarter revenues ranging between $18 million and $20 million, bringing its full-year revenue guidance to between $102.8 million and $104.8 million. That marked an anticipated year-over-year increase of between […]
Vapotherm prices public offering
VapoTherm (NYSE:VAPO) announced today that it priced an underwritten public offering of nearly 3.4 million shares of its common stock. According to a news release, the 3.35 million total shares of the Exeter, N.H.-based respiratory distress treatment developer will be sold at price of $26 per share. In addition, underwriters were granted 30-day option to purchase […]
VapoTherm prices $45m offering
VapoTherm (NYSE:VAPO) yesterday priced a stock offering worth up to $51.8 million for the maskless, noninvasive ventilation device it’s developing. Exeter, N.H.-based VapoTherm said it plans to float 3.1 million shares at $14.50 apiece for gross proceeds of $45.0 million. The offering also includes an underwriters option on another 465,750 shares, which would add $6.8 million […]
VapoTherm registers $57m offering
VapoTherm (NYSE:VAPO) yesterday registered a stock offering worth up to $57 million for the maskless, noninvasive ventilation device it’s developing. Exeter, N.H.-based VapoTherm said it plans to float 2.6 million shares at an unspecified price, listing the maximum amount of the offering at $57.4 million. The offering is also slated to include a 30-day underwriters option […]
Vapotherm launches Precision Flow Hi-VNI respiratory device
Vapotherm said today that it launched its next-gen Precision Flow Hi-VNI system intended to relieve respiratory stress in spontaneously breathing patients. The Exeter, N.H.-based company touted that the next-gen device features improvements to both its software and hardware intended to improve reliability. The Precision Flow Hi-VNI system is designed to deliver maskless noninvasive ventilation to […]
Vapotherm touts automated oxygen controller in preemie study
A recent clinical trial showed that Vapotherm’s (NYSE: VAPO) new IntellO2 module for its Precision Flow system greatly improved the chances of keeping premature babies in the target oxygenation range. The prospective, multi-center, controlled, order-randomized crossover trial demonstrated that using the IntellO2 module helped clinicians maintain newborns in the physician-prescribed oxygen saturation range 80% of the time, compared with 49 % […]
Vapotherm closes $64m IPO
Vapotherm said today it closed its initial public offering, raising a total $64.4 million in gross proceeds. The Exeter, N.H.-based company developed the Precision Flow line of devices to provide high-velocity heated, humidified and oxygenated air to treat patients with conditions such as pneumonia, chronic obstructive pulmonary disease, asthma and heart failure. Some 1,200 of […]
